The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in the field of hematopoietic cell transplantation (HCT). CIBMTR maintains a large outcomes registry with information for >475,000 HCT recipients in >420 centers and provides statistical support for analyzing those data. A separately funded Research Repository of donor-recipient specimens linked to these clinical data is available for a large subset of patients, as are data generated from analyses of these specimens, including high-resolution human leukocyte antigen (HLA) data and whole genome sequencing. Use of this Resource by thousands of investigators around the world during the current and previous funding cycles have contributed to >1,100 publications on important issues, to improved global collaboration in data exchange and HCT research and to increase the amount of data available to providers and patients for clinical decision-making. With renewal of U24-CA76518, CIBMTR will continue to build on the infrastructure made possible by this support to facilitate in-depth exploration of clinical, immunologic, genetic, quality of life, and health services issues related to HCT. This application proposes to enhance this Resource and to advance its utility through the following Specific Aims: Resource Development: Maintain and enhance CIBMTR?s high-quality clinical database and state-of-the-art statistical support to address important issues in HCT and related fields through continued development of state-of-the-art data collection, management and sharing technologies and procedures, expansion of infrastructure to capture patient-reported outcomes and cellular therapies, development and application of novel statistical techniques, and collaboration with national and international networks in HCT and related fields. Resource Utilization: Increase use of data and statistical resources maintained by the CIBMTR to support studies in malignant and non-malignant diseases with important clinical and policy implications, and enhance processes to prioritize and complete these studies.

Public Health Relevance

The CIBMTR plays a unique and important role in facilitating clinical research in HCT and cellular therapy. It is committed to developing its research database and statistical capabilities to meet the needs of investigators in a rapidly evolving field. It will build on the infrastructure made possible by support from U24-CA76518 and its partnerships to better serve the research and healthcare community and to address issues important to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA076518-23
Application #
9927601
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Henderson, Lori A
Project Start
1998-03-01
Project End
2023-02-28
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
23
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Medical College of Wisconsin
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Sureda, Anna; Zhang, Mei-Jie; Dreger, Peter et al. (2018) Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 124:1733-1742
Kumar, S K; Dispenzieri, A; Fraser, R et al. (2018) Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32:986-995
McCurdy, Shannon R; Zhang, Mei-Jie; St Martin, Andrew et al. (2018) Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv 2:299-307
Epperla, Narendranath; Ahn, Kwang Woo; Armand, Philippe et al. (2018) Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant 24:78-85
Inamoto, Yoshihiro; Petri?ek, Igor; Burns, Linda et al. (2018) Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Biol Blood Marrow Transplant :
Sahebi, Firoozeh; Garderet, Laurent; Kanate, Abraham S et al. (2018) Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant :
Pulsipher, Michael A; Logan, Brent R; Kiefer, Deidre M et al. (2018) Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors. Haematologica :
Jacobsohn, David A; Loken, Michael R; Fei, Mingwei et al. (2018) Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biol Blood Marrow Transplant 24:2040-2046
Lund, Troy C; Ahn, Kwang Woo; Tecca, Heather R et al. (2018) Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant :
Nemecek, Eneida R; Hilger, Ralf A; Adams, Alexia et al. (2018) Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood Biol Blood Marrow Transplant 24:1651-1656

Showing the most recent 10 out of 641 publications